ArticleClinical cancer research : an official journal of the American Association for Cancer Research2015

Phase I study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies.

Veronika Bachanova et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.